Taxol Resistance and its Reversal by Synthetic Isoprenoids in Human Bladder Cancer Cell Line

Abstract

Purpose: We investigated the mechanism of action of reversal agents for taxol-resistance in bladder cancers. Materials and Methods: We isolated a taxol-resistant cell line (KK47/TX30) from a human KK47 bladder cancer cell line (KK47/WT). We characterized KK47/TX30 cells and screened reversal agents for taxol-resistance. Results: KK47/TX30 cells exhibited approximately 700-fold resistance to taxol and cross-resistance to Vinca alkaloids and topoisomerase II inhibitors. Western blot analysis demonstrated P-glycoprotein (P-gp) overexpression in taxol-resistant cells. Drug accumulation and efflux studies showed that the decreased taxol accumulation in the resistant cell line was due to enhanced taxol efflux. We synthesized 31 isoprenoids based on the structure of N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine (SDB), which could completely reverse multidrug resistance (MDR) as shown previously. Among those examined, trans-N,N'-bis(3,4-dimethoxybenzyl)-N-solanesyl-1,2-diaminocyclohexane (N-5228) could completely reverse taxol-resistance in KK47/TX30 cells. Results of a structure-activity relationship study of isoprenoids suggested that the following structural features were important for overcoming taxol-resistance: (1) a basic structure of 8 to 10 isoprene units, (2) a cyclohexane ring or benzene ring within the framework, (3) two cationic sites in close proximity to each other, and (4) a benzyl group with 3,4-dimethoxy functionalities with moderate electron-donation. Conclusions: Taxol-resistance was primarily mediated by P-gp overexpression in KK47/TX30 cells. One of the synthetic isoprenoids, N-5228 could completely reverse taxol-resistance in KK47/TX30 cells.

Taxol-resistance - P-glycoprotein - isoprenoid - bladder cancer

References

• 1 Bremnes R M, Sundstrom S, Vilsvik J, Aasebo U. Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer.  J Clin Oncol. 2001;  19 3532-3538
• 2 Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A. et al . Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.  Urology. 2001;  58 59-64
• 3 Vaishampayan U, Flaherty L, Du W, Hussain M. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.  Cancer. 2001;  92 519-523
• 4 Zhou J, Cheng S C, Luo D, Xie Y. Study of multi-drug resistant mechanism in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.  Biochem Biophys Res Commun. 2001;  280 1237-1242
• 5 Ohta S, Nishio K, Kubota N, Ohmori T, Funayama Y, Ohira T. et al . Characterization of a taxol-resistant human small-cell lung cancer cell line.  Jpn J Cancer Res. 1994;  85 290-297
• 6 Horwitz S B, Cohen D, Rao S, Ringel I, Shen H J, Yang C P. Taxol: mechanisms of action and resistance.  J Natl Cancer Inst Monogr. 1993;  15 55-61
• 7 Dumontet C, Sikic B I. Mechanisms of action of and resistant to antitubulin agents: microtubule dynamics, drug transport, and cell death.  J Clin Oncol. 1999;  17 1061-1070
• 8 Nakagawa M, Akiyama S, Yamaguchi T, Shiraishi N, Ogata J, Kuwano M. Reversal of multidrug resistance by synthetic isoprenoids in the KB human cancer cell line.  Cancer Res. 1986;  46 4453-4457
• 9 Zhang L, Sachs C W, Fine R L, Casey P J. Interaction of prenylcysteine methyl esters with the multidrug resistance transporter.  J Biol Chem. 1994;  269 15 973-15 976
• 10 Wiese M, Pajeva I K. Structure-activity relationships of multidrug resistance reversers.  Curr Med Chem. 2001;  8 685-713